We can’t show the full text here under this license. Use the link below to read it at the source.
Immune responses after two inactivated COVID-19 vaccine doses, a heterologous third dose and subsequent boosting with bivalent mRNA in adults
Immune responses in adults after two inactivated COVID-19 vaccine doses, a different third dose, and later boosting with a two-strain mRNA vaccine
AI simplified
Abstract
Of 190 participants, the mRNA booster vaccine showed a 29.16 fold rise in neutralizing antibodies against the XBB.1.5 variant.
- Anti-Spike IgG levels increased at Day 28 after vaccination but decreased by Day 90.
- Neutralization antibody titers against the ancestral strain peaked at Day 90.
- The highest increase in neutralization titers against XBB.1.5 was observed in the mRNA vaccine subgroup.
- T-cell immunity, measured by IFN-γ production, rose comparably across all booster subgroups.
- Bivalent mRNA vaccination improved both antibody and T-cell responses in individuals primed with inactivated COVID-19 vaccines.
AI simplified
Key numbers
6.62
Increase in
Fold rise at Day 28 in subgroup after bivalent vaccination.
29.16×
against
Peak fold rise at Day 28 in subgroup.
5,277.24 mIU/mL
Median IFN-γ production
At Day 28 following bivalent vaccination.